The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...

The approval is supported by data from the COBLT study, FDA dockets and public information, and an observational database.

A dispute over the U.S. Food and Drug Administration's refusal to let two e-cigarette companies sell flavored vape products ...

A clinical trial study will give vets medical and commercial-grade cannabis products to look at “real-world” use and its ...

StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that the U.S. Food and Drug ...

More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each ...

Novocure has refined the transducer arrays that attach to Optune Gio, its wearable for glioblastoma treatment.

The U.S. Supreme Court will hear arguments Monday on whether to reinstate a federal ban on sweet-flavored vaping products.

Acoramidis is the first FDA-approved treatment for ATTR-CM with ... becomes the first and only approved product with a label specifying near-complete stabilization of TTR. "ATTR-CM is a ...

Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...

Regulators need to know that our most important health care problem is not that people are taking too many prescription drugs ...